Monte Rosa Therapeutics Inc (GLUE)

Nov 20, 2024

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - MSN

Nov 20, 2024

Nov 16, 2024

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024

Nov 13, 2024

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024

Nov 13, 2024

Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com

Nov 12, 2024

Nov 12, 2024

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance

Nov 11, 2024

Nov 11, 2024

Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat

Nov 11, 2024

Nov 09, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World

Nov 09, 2024

Nov 08, 2024

Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks

Nov 08, 2024

Nov 07, 2024

Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy

Nov 07, 2024

Nov 07, 2024

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN

Nov 07, 2024

Nov 07, 2024

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Nov 07, 2024

Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan

Nov 07, 2024

Oct 31, 2024

Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World

Oct 31, 2024

Oct 30, 2024

Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat

Oct 30, 2024

Oct 29, 2024

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance

Oct 29, 2024

Oct 29, 2024

Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma

Oct 29, 2024

Oct 29, 2024

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance

Oct 29, 2024

Oct 29, 2024

This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN

Oct 29, 2024

Oct 29, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN

Oct 29, 2024

Oct 29, 2024

Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal

Oct 29, 2024

Oct 29, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada

Oct 29, 2024

Oct 28, 2024

Novartis adds another degrader, this time from Monte Rosa - BioCentury

Oct 28, 2024

Oct 28, 2024

This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily

Oct 28, 2024

Oct 28, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat

Oct 28, 2024

Oct 28, 2024

Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online

Oct 28, 2024

Oct 28, 2024

Boston Biotech Announces Novartis Collaboration - Streetwise Reports

Oct 28, 2024

Oct 28, 2024

Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat

Oct 28, 2024

Oct 28, 2024

Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch

Oct 28, 2024

Oct 28, 2024

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN

Oct 28, 2024

Oct 28, 2024

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024

Oct 28, 2024

Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International

Oct 28, 2024

Oct 28, 2024

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart

Oct 28, 2024

Oct 28, 2024

Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals

Oct 28, 2024

Oct 28, 2024

Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart

Oct 28, 2024

Oct 28, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India

Oct 28, 2024

Oct 28, 2024

Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online

Oct 28, 2024

Oct 28, 2024

Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter

Oct 28, 2024

Oct 28, 2024

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive

Oct 28, 2024

Oct 28, 2024

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail

Oct 28, 2024

Oct 28, 2024

Monte Rosa Therapeutics, Inc Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Marketscreener.com

Oct 28, 2024

Oct 28, 2024

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs - Reuters

Oct 28, 2024

Oct 28, 2024

Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Yahoo Finance

Oct 28, 2024

Oct 28, 2024

Monte Rosa Therapeutics Shares Soar on Novartis Team-Up - Marketscreener.com

Oct 28, 2024

Oct 28, 2024

Monte Rosa jumps on $150M license deal with Novartis (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024

Oct 28, 2024

Monte Rosa inks $150 million Novartis deal for MRT-6160 By Investing.com - Investing.com Canada

Oct 28, 2024